First volunteers on COVID-19 human challenge study leave quarantine

The UK’s COVID-19 human challenge study has reached its first milestone after administering virus to three volunteers in a controlled clinical setting

The first participants recruited to the landmark trial have now completed a period of quarantine at the Royal Free Hospital in London. They will now continue to be monitored by the clinical team.  

Dr Andrew Catchpole, Chief Scientific Officer at hVIVO, part of Open Orphan plc said: “We would like to thank these volunteers for their participation in this important study and look forward to welcoming the following cohorts. We expect that this study will greatly assist our understanding of this disease and provide insights into its progression, natural immune response, and transmission. We look forward to publishing the study’s results in due course and moving forward with vaccine challenge studies later this year.”

Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data). 

Click to view all articles for the EPIC:
Or click to view the full company profile:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Open Orphan Plc

More articles like this

Open Orphan Plc

Open Orphan’s hVIVO launches its Disease in Motion platform

Open Orphan plc (LON:ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation and world leader in vaccine and antiviral testing using human challenge clinical trials, has announced that hVIVO, a subsidiary of Open Orphan, has officially launched its Disease in

Open Orphan Plc

Cathal Friel’s Open Orphan mulls Imutex cash-in

Speculation is mounting that Open Orphan, a clinical trial company headed by Irish dealmaker Cathal Friel, will move to spin off its stake in vaccine developer Imutex via a Nasdaq listing this year. Through its hVivo subsidiary, Open Orphan holds

Open Orphan Plc

Open Orphan subsidiary wins €7.5m contract to run study

Dublin-listed pharmaceutical services company Open Orphan’s subsidiary Hvivo has won a contract worth €7.5 million to run a human viral challenge study. Open Orphan, a European-focused, rare and orphan drug consulting services platform, is the result of executive chairman Cathal Friel reversing

Open Orphan Plc

Open Orphan’s hVIVO secures £7.5m RSV Human Challenge Study contract

Open Orphan plc (LON:ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation and world leader in vaccine and antiviral testing using human challenge clinical trials, has announced that hVIVO, a subsidiary of Open Orphan, has entered into a contract

Open Orphan Plc

Codagenix expands senior management team to support COVID-19 vaccine progress

Codagenix Inc., a clinical-stage biotechnology company developing prophylactic vaccines and oncolytic virus therapies, today announced the expansion of its senior management team with three new appointments. Lisa Runco, Ph.D., has been named Director of Operations. Additionally, Sally Yang, M.S., R.A.C.